Myriad Genetics (MYGN) Accumulated Expenses (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Accumulated Expenses data on file, last reported at $90.5 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $90.5 million, down 19.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.5 million (down 19.27% YoY), and the FY2025 annual result was $96.9 million, down 18.57% from the prior year.
• Accumulated Expenses retreated to $90.5 million in Q1 2026 per MYGN's latest filing, from $96.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $164.3 million in Q2 2023 and troughed at $84.4 million in Q2 2022.
• A 5-year average of $109.0 million and a median of $100.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 47.73% in 2022, then surged 94.67% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $94.3 million in 2022, then gained by 20.78% to $113.9 million in 2023, then gained by 4.48% to $119.0 million in 2024, then retreated by 18.57% to $96.9 million in 2025, then declined by 6.6% to $90.5 million in 2026.
• Business Quant data shows MYGN's Accumulated Expenses at $90.5 million in Q1 2026, $96.9 million in Q4 2025, and $108.3 million in Q3 2025.